The significance of the activity of CSF cholinesterases in dementias

Medical Hypotheses

Volumn 47, Issue 5, 1996, Pages 363-376

  Shen, Z X ^a,b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID; DEMENTIA; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HYPOTHESIS; PRIORITY JOURNAL; REVIEW;

EID: 0029797410     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(96)90216-9     Document Type: Article

References (104)

1. Selkoe D J. Normal and abnormal biology of the β-amyloid precursor protein. Annu Rev Neurosci 1994; 17: 489-517.
2. Corder E H, Saunders A M, Strittmatter W J et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1994; 261: 921-923.
3. Shen Z X. Acetylcholinesterase provides deeper insights into Alzheimer's disease. Med Hypotheses 1994; 43: 21-30.
4. Hermann C, Stern R G, Losonzcy M F, Jaff S, Davidson M. Diagnostic and pharmacological approaches in Alzheimer's disease. Drugs Aging 1991; 1: 144-162.
5. Mizukawa K, McGeer P L, Tago H, Peng J H, McGeer E G, Kimura H. The cholinergic system of the human hindbrain studied by choline acetyltransferase immunohistochemistry and acetylcholinesterase histochemistry. Brain Res 1986; 379: 39-55.
6. Mesulam M M, Geula C. Nucleus basalis (Ch4) and cortical cholinergic innervation in the human brain: observations based on the distribution of acetylcholinesterase and choline acetyltransferase. J Comp Neurol 1988; 275: 216-240.
7. Mesulam M M, Geula C. Acetylcholinesterase-rich pyramidal neurons in the human neocortex and hippocampus: absence at birth, development during the life span, and dissolution in Alzheimer's disease. Ann Neurol 1988; 24: 765-773.
8. Mesulam M M, Geula C. Acetylcholinesterase-rich neurons of the human cerebral cortex: cytoarchitectonic and ontogenetic patterns of distribution. J Comp Neurol 1991; 306: 193-220.
9. Mesulam M M, Geula C. Overlap between acetylcholinesterase-rich and choline acetyltransferase-positive (cholinergic) axons in human cerebral cortex. Brain Res 1992; 577: 112-120.
10. Yasuharo O, Nakamura S, Akiguchi I, Kimura J, Kameyama M. The distribution of senile plaques and acetylcholinesterase staining in the thalamus in dementia of Alzheimer type. Rinsho-Shinkeigaku Clin Neurol 1991; 31: 377-382.
11. Davies P. Neurotransmitter-related enzymes in senile dementia of the Alzheimer type. Brain Res 1979; 171 319-327.
12. Perry E K, Johnson M, Kerwin J M et al. Convergent cholinergic activities in aging and Alzheimer's disease. Neurobiol Aging 1992; 13: 393-400.
13. Aquilonius S M, Eckernas S A. Choline acetyltransferase in human cerebrospinal fluid - non-enzymatically and enzymatically catalyzed acetylcholine synthesis. J Neurochem 1976; 27: 317-318.
14. DeKosky S T, Scheff S W, Hachne C G. Acetylcholine synthesis in human CSF: implications for study of central cholinergic metabolism. Neurochem Res 1989; 14: 191-196.
15. Senut M C, Roudier M, Davous P, Fallet-Bianco C, Lamour Y. Quantitative analysis of the distribution of acetylcholinesterase-positive senile plaques in the hippocampal formation in patients with senile dementia of Alzheimer type. CR Acad Sci Se Iii, Sci Vie 1988; 306: 221-227.
16. Senut M C, Roudier M, Davous P, Fallet-Bianco C, Lamour Y. Senile dementia of the Alzheimer type: is there a correlation between entorhinal cortex and dentate gyrus lesions? Acta Neuropathol 1991; 82: 306-315.
17. Ulrich J, Meier-Ruge W, Probst A, Meier E, Ipsen S. Senile plaques: staining for acetylcholinesterase and A4 protein: a comparative study in the hippocampus and entorhinal cortex. Acta Neuropathol 1990; 80: 624-628.
18. Ulrich J. Histochemical representation of acetylcholinesterase in Alzheimer's disease. Acta Histochem 1992; 42 (Suppl): 11-12.
19. Nakamura S, Takemura M, Suenaga T et al. Occurrence of acetylcholinesterase activity closely associated with amyloid beta/A4 protein is not correlated with acetylcholinesterase-positive fiber density in amygdala of Alzheimer's disease. Acta Neuropathol 1992; 84: 425-432.
20. Gomez-Ramos P, Mufson E J, Moran M A. Ultrastructural localization of acetylcholinesterase in neurofibrillary tangles, neuropil threads and senile plaques in aged and Alzheimer's brain. Brain Res 1992; 569: 229-237.
21. Moran M A, Mufson E J, Gomaz-Ramos P. Colocalization of cholinesterases with beta amyloid protein in aged and Alzheimer's brains. Acta Neuropathol 1993; 85: 362-369.
22. Johnson S, Domino E F. Cholinergic enzymatic activity of cerebrospinal fluid of patients with various neurologic diseases. Clin Chim Acta 1971; 35: 421-428.
23. Yaksh T L, Filbert M G, Harris L W, Yamamura H I. Acetylcholinesterase turnover in brain, cerebrospinal fluid and plasma. J Neurochem 1975; 25: 853-860.
24. Cubb I W, Goodman S, Smith A D. Is acetylcholinesterase secreted from central neurons into the cerebrospinal fluid? Neuroscience 1976; 1: 57-62.
25. Bareggi S R, Giacobini E. Acetylcholinesterase activity in ventricular and cisternal CSF of dogs. J Neurosci Res 1978; 3: 335-339.
26. Greenfield S A, Smith A D. The influence of electrical stimulation of certain brain regions on the concentration of acetylcholinesterase in rabbit cerebrospinal fluid. Brain Res 1979; 177: 445-459.
27. Atack J R, May C, Kaye J A, Kay A D, Rapoport S I. Cerebrospinal fluid cholinesterases in aging and in dementia of the Alzheimer type. Ann Neurol 1988; 23: 161-167.
28. Vogt M, Smith A D, Fuenmayor L D. Factors influencing the cholinesterases of cerebrospinal fluid in the anaesthetized cat. Neuroscience 1988; 12: 979-995.
29. Greenfield S A. Acetylcholinesterase may have novel functions in the brain. TINS 1984; 7: 364-368.
30. Brimijoin S. Molecular forms of acetylcholinesterase in brain, nerve muscle: nature, localization and dynamics. Prog Neurobiol 1983; 21: 291-322.
31. Atack J R, Perry E K, Bonham J R, Candy J M, Perry R H. Molecular forms of acetylcholinesterase in the aged human central nervous system. J Neurochem 1986; 47: 263-277.
32. Atack J R, Perry E K, Bonham J R, Perry R H. Molecular forms of acetylcholinesterase and butyrylcholinesterase in human plasma and cerebrospinal fluid. J Neurochem 1987; 48: 1845-1850.
33. Rakonczay Z. Cholinesterase and its molecular forms in pathological states. Prog Neurobiol 1988; 31: 311-330.
34. Silver A. The biology of cholinesterases. In: Neuberger A, Tatum E L, eds. Frontiers of Biology, vol. 36. Amsterdam: North Holland, 1974.
35. Massoulie J, Bon S. The molecular forms of cholinesterase and acetylcholinesterase in vertebrates. Annu Rev Neurosci 1982; 5: 57-106.
36. Wright C, Ceula C, Mesulam M M. Neuroglial cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles, and patterns of selective vulnerability. Ann Neurol 1993; 34: 373-384.
37. Mesulam M M, Geula C. Butyrylcholinesterase activity differentiates the amyloid plaques of aging from those of dementia. Ann Neurol 1994; 36: 722-727.
38. Perry E K, Perry R H, Blessed G, Tomlinson B E. Changes in brain cholinesterase in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol 1978; 4: 273-277.
39. Wright C, Geula C, Mesulam M M. Properties of cholinesterases in brain with Alzheimer's disease and components of whole blood. Abstracts 18, pp 738. Society for Neuroscience 22nd Annual Meeting, October 25-30 1992, Anaheim, California.
40. Yates C M, Simpson J, Gordon A, Christie J E. Cholinergic enzymes in the spinal cord in Alzheimer-type dementia. J Neural Transm 1989; 1: 311-315.
41. Elble R, Giacobini E, Scarsellaa G F. Cholinesterase in cerebrospinal fluid. A longitudinal study in Alzheimer's disease. Arch Neurol 1987; 44: 403-407.
42. Urakami K, Adachi E, Awaki E, Takahashi K. Characterization of the course of senile dementia of the Alzheimer type using cerebrospinal fluid levels of acetylcholinesterase and somatostatin. Acta Neurol Scand 1989; 80: 232-237.
43. Ellman G L, Courtney K D, Andrews V Jr, Featherstone R M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961; 7: 88-95.
44. Johnson C D, Russell R L. A rapid, simple radiometric assay for cholinesterase, suitable for multiple determinations. Anal Biochem 1975; 64: 229-238.
45. Fonnum F. Radiochemical assays for choline acetyltransferase and acetylcholinesterase. In: Rodnight R, Marks N, eds. Research Methods in Neurochemistry, 3rd edn. New York, Plenum, 1975: 253-275.
46. Elble R, Giacobini E, Higgins C. Choline levels are increased in cerebrospinal fluid of Alzheimer patients. Neurobiol Aging 1989; 10: 45-50.
47. Kumar V, Giacobini E, Markwell S. CSF choline and acetylcholinesterase in early-onset vs late-onset Alzheimer's disease patients. Acta Neurol Scand 1989; 80: 461-466.
48. Shen Z X, Ding Q, Wei G Z, Ding M C, Meng J M. CSF cholinesterase in early-onset and late-onset Alzheimer's disease and multi-infarct dementia of Chinese patients. Acta Neurol Scand 1993; 87: 19-24.
49. Shen Z X. Acetylcholinesterase in Alzheimer's disease. MSc thesis. Oxford University, England, 1992.
50. Reinikainen K J, Riekkinen P J, Paljarvi L et al. Cholinergic deficit in Alzheimer's disease: a study based on CSF and autopsy data. Neurochem Res 1988; 13: 135-146.
51. Hartikainen P, Soininen H, Reinikainen K J, Sirvio J, Soikkeli R, Riekkinen P J. Neurotransmitter markers in the cerebrospinal fluid of normal subjects effects of aging and other confounding factors. J Neural Transm [GenSect] 1991; 84: 103-107.
52. Atack J R, Litvan I, Thai L J, May C, Rapoport S I, Chase T N. Cerebrospinal fluid acetylcholinesterase in progressive supranuclear palsy: reduces activity relative to normal subjects and lack of inhibition by oral physostigmine. J Neurol Neurosurg Psychiatry 1991; 54: 832-835.
53. Lal S, Wood P L, Kiely M E et al. CSF acetylcholinesterase in dementia and in sequential samples of lumbar CSF. Neurobiol Aging 1984; 5: 269-274.
54. Nakano S, Kato T, Nakamura S, Kameyama M. Acetylcholinesterase activity in cerebrospinal fluid of patients with Alzheimer's disease and senile dementia. J Neurol Sci 1986; 75: 213-223.
55. Deutsch S I, Mohrs R C, Levy M I et al. Acetylcholinesterase activity in CSF in schizophrenia, depression, Alzheimer's disease, and normals. Biol Psychiatry 1983; 18: 1363-1373.
56. Appleyard M E, Smith A D, Wilcock G K, Esiri M M. Decreased CSF acetylcholinesterase activity in Alzheimer's disease. Lancet 1983; ii: 452.
57. Appleyard M E, Smith A D, Berman P et al. Cholinesterase activities in cerebrospinal fluid of patients with senile dementia of Alzheimer type. Brain 1987; 110: 1309-1322.
58. Huff F J, Reiter C T, Rosen J, Peters J, van Kammen D P. No effect of haloperidol on cerebrospinal fluid acetylcholinesterase in patients with schizophrenia. Biol Psychiatry 1988; 24: 701-704.
59. Goldman J, Cote L. Aging of the brain: dementia of the Alzheimer's type. In: Kandel E R, Schwartz J H, Jessell T M, eds. Principles of Neural Science, 3rd edn. New York: Elsevier, 1991: 974-983.
60. Kawakatsu S, Morinobu S, Shinohara M, Totsuka S, Kobashi K. Acetylcholinesterase activities and monoamine metabolite levels in the cerebrospinal fluid of patients with Alzheimer type. Biol Psychiatry 1990; 28: 387-400.
61. Huff F J, Maire J C, Growdon J H, Corkin S, Wurtman R J. Cholinesterases in cerebrospinal fluid: correlations with clinical measures in Alzheimer's disease. J Neurol Sci 1986; 72: 121-129.
62. Soininen H, Halonen T, Riekkinen P J. Acetylcholinesterase activities in cerebrospinal fluid of patients with senile dementia of Alzheimer's disease. Acta Neurol Scand 1981; 64: 217-224.
63. Wood P L, Etienne P, Lal S, Gaauthier S, Cajal S, Nair NPV. Reduced lumbar CSF somatostatin level in Alzheimer disease. Life Sci 1982; 31: 2073-2079.
64. Soininen H, Pitkanen A, Halonen T, Riekkinen PJ. Dopamine-hydroxylase and acetylcholinesterase activities of cerebrospinal fluid in Alzheimer's disease. Acta Neurol Scand 1984; 69: 29-34.
65. Soininen H S, Jolkkonen J T, Reinikainen K J, Halonen T O, Riekkinen P J. Reduced cholinesterase activity and somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with dementia of the Alzheimer type. J Neurol Sci 1984; 63: 167-172.
66. Riekkinen P J, Soininen H, Sirvio J, Reinikainen K, Helkala E L, Paljarvi L. Dementia without cholinergic deficit. Gerontology 1987; 33: 268-272.
67. Hartikainen P, Reinikainen K J, Soininen H, Sirvio J, Soikkeli R, Riekkinen P J. Neurochemical markers in the cerebrospinal fluid of patients with Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis and normal controls. J Neural Transm (P-D Sect) 1992; 4: 53-68.
68. Marquis J K, Volicer L, Mark K A, Direnfeld L K, Freedman M. Cholinesterase activity in plasma, erythrocytes and cerebrospinal fluid of patients with dementia of the Alzheimer type. Biol Psychiatry 1985; 520: 605-610.
69. Tune L, Gueker S, Folstein M, Oshioda L, Coyle J I. Cerebrospinal fluid acetylcholinesterase activity in senile dementia of Alzheimer's type. Ann Neurol 1985; 17: 46-48.
70. Yoshinaga J, Sasaki T, Ideshita H, Hikiji A, Kuwaki T. Acetylcholinesterase activity in CSF in senile dementia of Alzheimer type, vascular dementia, and parkinson's disease. Rinsho-Shinkeigaku Clin Neurol 1989; 29: 376-378.
71. Sirvio J, Rakonczay Z, Hartikainen P, Kasa P, Riekkinen P J. The molecular forms of acetylcholinesterase in cerebrospinal fluid of normal subjects - effect of aging. J Neural Transm 1991; 86: 147-150.
72. Decker M W. The effects of aging on hippocampal and cortical projections of the forebrain cholinergic system. Brain Res 1987; 12: 423-438.
73. Ulrich J. Alzheimer changes in nondemented patients younger than sixty-five: possible early stages of Alzheimer's disease and senile dementia of Alzheimer type. Ann Neurol 1985; 17: 273-277.
74. Crystal H, Dickson D, Fuld P et al. Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology 1988; 38: 1682-1687.
75. Morlis J C, Fulling K. Early Alzheimer's disease. Arch Neurol 1988; 45: 345-349.
76. Morris J C, McKeel D W Jr, Storandt M et al. Very mild Alzheimer's disease: informant-based clinical, psychometric, and pathologic distinction from normal aging. Neurology 1991; 41: 469-478.
77. Morris J C, Storandt M, Mckeel D W Jr, Rubin E H, Grant E A. Normal aging versus very mild Alzheimer's disease: clinico-pathologic distinctions. Neurobiol Aging 1994; 15 (suppl): S140.
78. Shoji M, Golde T E, Ghiso J et al. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science 1992; 258: 126-129.
79. Jobst K A, Smith A D, Szatmari M et al. Detection in life of confirmed Alzheimer's disease using a simple measurement of medial temporal lobe atrophy by computed tomography. Lancet 1992; 340: 1179-1183.
80. Mann D M A, Esiri M M. The site of the earliest lesions of Alzheimer's disease. N Engl J Med 1989; 318: 789-790.
81. Motte J, Williams R S. Age-related changes in the density and morphology of plaques and neurofibrillary tangles in Down syndrome brain. Acta Neuropathol (Berl) 1989; 77: 535-546.
82. Rumble B, Retallack R, Hilbich C et al. Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease. N Engl J Med 1989; 320: 1446-1452.
83. Murphy M. The molecular pathogenesis of Alzheimer's disease: clinical prospects. Lancet 1992; 340: 1512-1515.
84. Bondareff W. Age and Alzheimer disease. Lancet 1983; i: 1447.
85. Bisso G M, Masullo C, Michalek H, Silveri M C, Pocchiari M. Molecular forms of cholinesterases in CSF of Alzheimer's disease/senile dementia of Alzheimer type patients and matched neurological controls. Life Sci 1986; 38: 561-567.
86. Gomez S, Davons P, Faivre-Bauman A et al. Acetylcholinesterase activity and somatostatin-like immunoreactivity in lumbar cerebrospinal fluid of demented patients. Psychoneuroendocrinology 1986; 11: 69-73.
87. Tomlinson B E, Blessed S, Roth M. Observations on the brain of demented old people. J Neurol Sci 1970; 11: 205-242.
88. Ulrich J, Probst A, Wuest M. The brain diseases causing senile dementia: a morphological study on 54 consecutive autopsy cases. J Neurol 1986; 233: 118-122.
89. Jellinger K, Danielczyk W, Fischer P, Gabriel E. Clinico-pathological analysis of dementia disorders in the elderly. J Neurol Sci 1990; 95: 239-258.
90. Hachinski V. The decline and resurgence of vascular dementia. Can Med Assoc J 1990; 142: 107-111.
91. Hachinski V. Preventable senility: a call for action against the vascular dementia's. Lancet 1992; 340: 645-648.
92. Merriam A E, Aronson M K, Gaston P, Wey S L, Katz I. The psychiatric symptoms of Alzheimer's disease. J Assoc Med Geriatr Soc 1988; 36: 7-12.
93. Wragg R E, Jeste D V. Overview of depression and psychosis in Alzheimer's disease. Am J Psychiatry 1989; 146: 577-587.
94. Relman A S. Tacrine as a treatment for Alzheimer's dementia. N Engl J Med 1991; 324: 349-352.
95. Holttum J R, Gershon S. The cholinergic model of dementia, Alzheimer type: progression from the unitary transmitter concept. Dementia 1992; 3: 174-185.
96. Wright C, Guela C, Mesulam M M. Protease inhibitors and indoleamine selectively inhibit cholinesterases in the histopathologic structures of Alzheimer's disease. Proc Natl Acad Sci USA 1993; 90: 683-686.
97. Loewenstein-Lichtenstein Y, Schwarz M, Click D, Norgraard-Pedersen B, Zakut H, Soreq H. Genetic predisposition to adverse consequences of anti-cholinesterases in 'atypical' BChE carriers. Nature Med 1995; 1: 1082-1085.
98. Winker M A. Tacrine for Alzheimer's disease Which patient, what dose? JAMA 1994; 271: 1023-1024.
99. Knapp M J, Knopman D S, Solomon P R, Pendlebury W W, Davis C S, Gracon S I. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994; 271: 985-991.
100. Keeler J R, Hurst C G, Dunn M A. Pyridostigmine used as a nerve agent pretreatment under wartime conditions. JAMA 1991; 266: 693-695.
101. Watkins P B, Zimmerman H J, Knapp M J, Gracon S I, Lewis K W. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994; 271: 992-998.
102. Gavaghan H. NIH panel rejects Persian Gulf syndrome. Nature 1994; 369: 8.
103. Arendt T, Bigl V, Walther F, Sonntag M. Decreased ratio of CSF acetylcholinesterase to butyrylcholinesterase activity in Alzheimer's disease. Lancet 1984; ii: 173.
104. Khachaturian Z S. Diagnosis of Alzheimer's disease. Arch Neurol 1985; 42: 1097-1105.